Thomas E. Keane, MD

Thomas E. Keane, MD

Medical University of South Carolina

Charleston, South Carolina

Thomas E. Keane, MD, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator or co-investigator on more than 20 major clinical and preclinical studies. Much of his work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate the efficacy of new therapies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a United States patent for sphingolipid derivatives and their use. Dr. Keane’s research has led to publication of more than 100 articles peer-reviewed in such journals as The Journal of Urology, Urologic Oncology, and the Journal of Vascular Surgery. He provides editorial services to publications ranging from Urology to the International Journal of Cancer and is co-editor of the text Glenn’s Urologic Surgery, 6th, 7th, and 8th Editions. He is an accomplished speaker, having delivered many presentations to professional societies and symposia throughout the United States and abroad.

Disclosures:

Articles by Thomas E. Keane, MD

Panel on Androgen Deprivation Therapy: A Closer Review of the Cardiovascular Risk

Panel on Androgen Deprivation Therapy: A Closer Review of the Cardiovascular Risk

Posted by | Jun 2020

Thomas E. Keane, MD, Professor and Chairman of the Department of Urology at the Medical University of South Carolina, Charleston, leads a panel discussion including Lawrence I. Karsh, MD, Peter J. Rossi, MD, and Neal D. Shore, MD, FACS, to discuss the process of treating prostate cancer in a patient who is at risk for cardiovascular disease and how extra care is needed in such cases. They also stress the importance of being in contact with a patient’s PCP even if one chooses to do their own assessment of patient risk, as well as when ADT should not be considered an option, such as in the case of a patient with significant CAD and elevated liver enzymes. The group, over the course of the panel, discuss the many ADT options available, including their strengths and weaknesses.

Read More
Androgen Deprivation Therapy: A Closer Review of the Role of Anti-Androgens

Androgen Deprivation Therapy: A Closer Review of the Role of Anti-Androgens

Posted by | May 2020

Thomas E. Keane, MD, Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston, discusses the role of anti-androgens in androgen deprivation therapy (ADT). Dr. Keane looks at some studies out of Canada showing the ideal T levels during ADT, but goes on to point out that both the FDA and EU regulatory authorities do not follow these guidelines. He emphasizes throughout his talk why this is problematic and why doctors should be following the Canadian guidelines. He also goes over some of the adverse effects of ADT and emphasizes the increased risk for cardiovascular and liver disease. Dr. Keane goes on to discuss different clinical data that show how to address these risks.

Read More
Timing of ADT with Chemotherapy in 2019

Timing of ADT with Chemotherapy in 2019

Posted by | Jun 2019

Thomas E. Keane, MD, reviews the data supporting and opposing the advancement of chemotherapy into the metastatic castration-sensitive prostate cancer (mCSPC) disease state. He then discusses a current trial introducing chemotherapy in patients prior to androgen deprivation therapy (ADT).

Read More
Timing of ADT and Chemotherapy

Timing of ADT and Chemotherapy

Posted by | Apr 2018

Thomas E. Keane, MD, discusses how the current prostate cancer treatment paradigm is evolving. He argues for moving androgen deprivation therapy (ADT) upfront in a patient’s treatment, but also acknowledges this approach could potentially hinder responsiveness to second-line therapies.

Read More

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Find Us:
375 Greenbrier Drive, Suite 100
Charlottesville, VA 22901

Call Us:
434-817-2000

Email Us:
Send Message

INFO

Privacy Policy
Terms & Conditions

Your GRU

– Account Dashboard
– Your Courses

Exercise & Wellness

Associate Editors


Fred Bartlit, Esq.
StrongPath


Mark A. Moyad, MD, MPH
University of Michigan
Ann Arbor, Michigan